BridgeMD
New treatment option for Cigarette Smoking
Official title Mobile Health Technology for Personalized Tobacco Cessation Support in Laos
ClinicalTrials.gov ID: NCT05233228
What this study is testing
What is Nicotine patch?
Nicotine patch is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for cigarette smoking.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In Lao People's Democratic Republic (Lao PDR), 51% of adult men and 7% of adult women smoke tobacco. The development and evaluation of sustainable tobacco cessation interventions suitable for widespread adoption in nations such as Lao PDR are pressing public health needs.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 3 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- (pilot RCT in the R21 Phase and main RCT in the R33 Phase):
- aged ≥18 years
- self-reported current combustible cigarette smokers (smoked at least 100 cigarettes in lifetime and currently smoke ≥1 cigarette/day)
- willing to set a quit date within 2 weeks of study enrollment
- able to provide written informed consent to participate
You likely can't join if
- (pilot RCT in the R21 Phase and main RCT in the R33 Phase)
- history of a medical condition that precludes use of NRT
- ineligibility to participate based on medical or psychiatric conditions diagnosed by a physician/clinician
- enrollment in another cessation program or current use of other cessation medications.
See the full eligibility criteria
- (pilot RCT in the R21 Phase and main RCT in the R33 Phase):
- aged ≥18 years
- self-reported current combustible cigarette smokers (smoked at least 100 cigarettes in lifetime and currently smoke ≥1 cigarette/day)
- willing to set a quit date within 2 weeks of study enrollment
- able to provide written informed consent to participate
- able to read Lao (score ≥4 points on the Rapid Estimate of Adult Literacy in Medicine-Short Form).
- (pilot RCT in the R21 Phase and main RCT in the R33 Phase)
- history of a medical condition that precludes use of NRT
- ineligibility to participate based on medical or psychiatric conditions diagnosed by a physician/clinician
- enrollment in another cessation program or current use of other cessation medications.
The study team makes the final eligibility decision.
Where it's taking place
- Champasak, Laos
- Vientiane, Laos
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 3 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Champasak, Laos; Vientiane, Laos. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.